Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

NCT05176483 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

1314

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma (RCC)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Urothelial Carcinoma (UC)
Solid Tumor
Hepatocellular Carcinoma (HCC)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Clear Cell Renal Cell Carcinoma (ccRCC)
Non-Clear Cell Renal Cell Carcinoma (nccRCC)

Interventions

DRUG: Zanzalintinib
DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Nivolumab
DRUG: Nivolumab + Relatlimab

Sponsor

Exelixis